Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 94 of 144 pages ‹ First < 92 93 94 95 96 > Last ›
HSL5045
Cardarelli R, Licciardone JC, Taylor LG.
A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
BMC Fam Pract 2006 Mar 3; 7:(13):
http://www.biomedcentral.com/1471-2296/7/13
HSL5492
There is no "Away" - Pharmaceuticals, Personal Care Products, and Endocrine-Disrupting Substances: Emerging Contaminants Detected in Water
Canadian Institute for Environmental Law andPolicy ( see http://www.cielap.org/ ) 2006 Mar 3
http://cielap.org/pdf/NoAway.pdf
HSL3841
Stanford Doctors Spotlight Fatal Flaw in Multiple Sclerosis Drug Trial
Home Business Wire 2006 Mar 2
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060302005234&newsLang=en
HSL3845
Goozner M.
Oncologists Rebel Against Amgen's Marketing Tactics
GoozNews 2006 Mar 2
http://www.gooznews.com/
HSL4546
Hilliard T, Chambers T.
The relationship between paediatricians and commerce.
Paediatr Respir Rev 2006 Mar; 7:(1):54-9
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00086-2
HSL4548
Netzer T.
European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
Eur J Cancer 2006 Mar; 42:(4):446-55
HSL4860
Jeppsson A.
[Drug development costs are overstated by the industry].
Lakartidningen 2006 Mar 1-7; 103:(9):663-4
HSL4862
Anderson JC, Narus JA, van Rossum W.
Customer value propositions in business markets.
Harv Bus Rev 2006 Mar 01; 84:(3):90-9,
HSL4976
Boyce P.
Restoring wisdom to the practice of psychiatry.
Australas Psychiatry 2006 Mar 01; 14:(1):3-7
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1665.2006.02241.x
HSL4983
Sikora C.
Whose pen is in your pocket?
Can Fam Physician 2006 Mar 01; 52:394-5
HSL4985
Drowning or thirsting: the extremes of availability of medical information.
PLoS Med 2006 Mar 01; 3:(3):e165
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030165
HSL4986
Smith R.
The trouble with medical journals.
J R Soc Med 2006 Mar 01; 99:(3):115-9
http://www.jrsm.org/cgi/content/full/99/3/115
HSL4989
Leather DA, Davis SC.
Paediatricians and the pharmaceutical industry: an industry perspective of the challenges ahead.
Paediatr Respir Rev 2006 Mar 01; 7:(1):60-6
http://linkinghub.elsevier.com/retrieve/pii/S1526-0542(05)00117-X
HSL5131
Engelman K.
Rx: professional integrity (prn).
J Clin Hypertens (Greenwich) 2006 Mar 01; 8:(3):232
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3351&uid=16578956&db=PubMed&url=http://www.lejacq.com/articleDetail.cfm?pid=JClinHypertens_8;3:232
HSL5143
Pickering TG.
Class effects and labeling of antihypertensive drugs.
J Clin Hypertens (Greenwich) 2006 Mar 01; 8:(3):215-20
http://www.lejacq.com/Search_ArticleDetail.cfm?PID=JClinHypertens_8;3:215&CFID=1084529&CFTOKEN=12638004
HSL5158
Levin PJ, McGee G.
Physician, divest thyself.
Am J Bioeth 2006 Mar-Apr 01; 6:(2):1-2
http://taylorandfrancis.metapress.com/(xejiig55vu0ome45n4xojl45)/app/home/contribution.asp?referrer=parent&backto=issue,1,44;journal,2,25;linkingpublicationresults,1:111605,1
HSL5159
Salerno RA, Lesko LJ.
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Pharmacogenomics J 2006 Mar-Apr 01; 6:(2):78-81
http://www.nature.com/tpj/journal/v6/n2/abs/6500345a.html
HSL5219
Mack J.
Counterpoint: biotech needs more than DTC as usual.
Nat Biotechnol 2006 Mar 01; 24:(3):267
http://www.nature.com/nbt/journal/v24/n3/full/nbt0306-267.html
HSL5220
Oestreicher P, Warner T.
Point: Biotech needs direct to consumer communications.
Nat Biotechnol 2006 Mar 01; 24:(3):265-6
http://www.nature.com/nbt/journal/v24/n3/full/nbt0306-265b.html
HSL5375
Ruiz JG, Mintzer MJ, Leipzig RM.
The impact of E-learning in medical education.
Acad Med 2006 Mar 01; 81:(3):207-12
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1040-2446&volume=81&issue=3&spage=207
HSL5394
Toure JT, Brandt NJ, Limcangco MR, Briesacher BA.
Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities.
Am J Geriatr Pharmacother 2006 Mar 01; 4:(1):25-35
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7CWH-4K21XJX-4&_coverDate=03%2F31%2F2006&_alid=421182227&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=18107&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=31062f4086f658175dddcec0c0b8359b
HSL5443
Ferrara J.
Personalized medicine: challenges in assessing and capturing value in the commercial environment.
Expert Rev Mol Diagn 2006 Mar 01; 6:(2):129-31
http://www.future-drugs.com/doi/abs/10.1586/14737159.6.2.129
HSL5556
Kolch M, Lippert HD, Fegert JM.
[The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Z Kinder Jugendpsychiatr Psychother 2006 Mar 01; 34:(2):117-26
HSL5557
Wick JY, Zanni GR.
Biogenerics: potential benefits and obstacles.
Consult Pharm 2006 Mar 01; 21:(3):208-12,
HSL5665
Dandona L.
Clinical trials in India: balancing economic opportunity with the public health context.
Natl Med J India 2006 Mar-Apr 01; 19:(2):57-9
HSL5672
Winterstein AG, Hartzema AG, Johns TE, De Leon JM, McDonald K, Henshaw Z, Pannell R.
Medication safety infrastructure in critical-access hospitals in Florida.
Am J Health Syst Pharm 2006 Mar 1; 63:(5):442-50
http://www.ajhp.org/cgi/content/full/63/5/442
HSL5673
Traynor K.
FDA resurrects, finalizes labeling rule.
Am J Health Syst Pharm 2006 Mar 1; 63:(5):398,
http://www.ajhp.org/cgi/content/full/63/5/398
HSL5778
Nunn AD.
The cost of developing imaging agents for routine clinical use.
Invest Radiol 2006 Mar 01; 41:(3):206-12
http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00004424-200603000-00002
HSL5833
Macdonald AJ.
Financial support and conflict of interest.
Br J Psychiatry 2006 Mar 01; 188:294
http://bjp.rcpsych.org/cgi/content/full/188/3/294
HSL6074
DeSilets LD.
Commercial support for professional development.
J Contin Educ Nurs 2006 Mar-Apr 01; 37:(2):52-3
HSL6076
Felsenfeld AL.
How sweet it isn't.
J Calif Dent Assoc 2006 Mar 01; 34:(3):193-4
HSL6086
Demonaco HJ, Ali A, Hippel E.
The major role of clinicians in the discovery of off-label drug therapies.
Pharmacotherapy 2006 Mar 01; 26:(3):323-32
http://www.atypon-link.com/doi/abs/10.1592/phco.26.3.323
HSL6087
Joppi R, Bertele V, Garattini S.
Orphan drug development is progressing too slowly.
Br J Clin Pharmacol 2006 Mar 01; 61:(3):355-60
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2125.2006.02579.x
HSL6088
Aronson JK.
Rare diseases and orphan drugs.
Br J Clin Pharmacol 2006 Mar 01; 61:(3):243-5
HSL6143
Carvalho MC, Accioly Junior H, Raffin FN.
[Social representations of generic drugs by consumers from Natal, Rio Grande do Norte, Brazil].
Cad Saude Publica 2006 Mar 01; 22:(3):653-61
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2006000300020&tlng=es&lng=en&nrm=iso
HSL6269
Grabowski HG, Wang YR.
The quantity and quality of worldwide new drug introductions, 1982-2003.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):452-60
http://content.healthaffairs.org/cgi/content/full/25/2/452
HSL6270
Ridley DB, Kramer JM, Tilson HH, Grabowski HG, Schulman KA.
Spending on postapproval drug safety.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):429-36
http://content.healthaffairs.org/cgi/content/full/25/2/429
HSL6271
Adams CP, Brantner VV.
Estimating the cost of new drug development: is it really 802 million dollars?
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):420-8
http://content.healthaffairs.org/cgi/content/full/25/2/420
HSL6272
Ridley DB, Grabowski HG, Moe JL.
Developing drugs for developing countries.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):313-24
http://content.healthaffairs.org/cgi/content/full/25/2/313
HSL6273
Drugs and vaccines around the world.
Health Aff (Millwood) 2006 Mar-Apr 01; 25:(2):312
http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?itool=Citation-def&PrId=3051&uid=16522572&db=PubMed&url=http://content.healthaffairs.org/cgi/pmidlookup?view=long&pmid=16522572
HSL4632
Doran E, Kerridge I, McNeill P, Henry D.
Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia.
Soc Sci Med 2006 Mar; 62:(6):1510-9
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-4H21NFX-1&_coverDate=03%2F31%2F2006&_alid=400810064&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=165ba1a1d91dd24eb1902c511a325900
HSL4869
Maclure M, Nguyen A, Carney G, Dormuth C, Roelants H, Ho K, Schneeweiss S.
Measuring prescribing improvements in pragmatic trials of educational tools for general practitioners.
Basic Clin Pharmacol Toxicol 2006 Mar; 98:(3):243-52
Randomized pragmatic trials of drugs, physician education and drug policies are needed to improve pharmacosurveillance and cost-effectiveness of prescribing. Since 1994, we have developed and tested methods for low-cost education and policy trials to improve prescribing in primary care in Canada. We review methodology for using drug claims and other health services data to evaluate prescribing improvement programs and policies. We apply the lessons to a proposed trial of physician education tools (PET) for quality improvement of prescribing. Design issues for the trial include defining the potential programme in causal terms using counterfactuals, narrowing the denominator to the population affected, excluding noise from the numerator, calculating the prescribing preference, adjusting for baseline differences, controlling for modifiers and confounders, accounting for uncertainty when measuring impacts, and grouping practices for feedback and recognition. Data from a randomized trial of academic detailing illustrate measurement challenges. A decade of progress on methods for evaluating prescribing improvement programs with drug claims data has enabled planning of routine randomized pragmatic trials of education and policies in primary care in Canada.
HSL4876
Hoodia: lose weight without feeling hungry?
Consum Rep 2006 Mar; 71:(3):49
HSL4926
Smith CA, Coyle ME.
Recruitment and implementation strategies in randomised controlled trials of acupuncture and herbal medicine in women's health.
Complement Ther Med 2006 Mar; 14:(1):81-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3048&uid=16473758&db=PubMed&url=http://linkinghub.elsevier.com/retrieve/pii/S0965-2299(05)00080-4
HSL5067
Somberg JC.
Pharmaceutical companies and medical therapeutics education.
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3159&uid=16645422&db=PubMed&url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00045391-200603000-00001 Am J Ther 2006 Mar-Apr; 13:(2):93
HSL5072
Lohiya S.
A simple stratification & storage system for samples and supplies.
J Natl Med Assoc 2006 Mar; 98:(3):405-7
HSL5076
Kim PS.
Reply to 'Truth in numbers'.
Nat Med 2006 Mar; 12:(3):269
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=16520764&db=PubMed&url=http://dx.doi.org/10.1038/nm0306-269a
HSL5077
Wadman M.
One year after launch, drug safety board is dubbed a failure.
Nat Med 2006 Mar; 12:(3):258
http://www.nature.com/doifinder/10.1038/nm0306-258b
HSL7414
Consumers Union of the US
Prescription for Change
: Consumers Union of the US 2006 Mar
http://www.consumersunion.org/pdf/drugreps.pdf
HSL7701
Morgan SG, McMahon M, Mitton C, Roughead E, Kirk R, Kanavos P, Menon D.
Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
Health Aff (Millwood) 2006 Mar-Apr; 25:(2):337-47
http://content.healthaffairs.org/cgi/content/full/25/2/337
HSL10881
Lobo FS, Wagner S, Gross CR, Schommer JC.
Addressing the issue of channeling bias in observational studies with propensity scores analysis.
Res Social Adm Pharm 2006 Mar; 2:(1):143-51
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17138506&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL10882
Altagracia-Martinez M, Kravzov-Jinich J, Guadarrama-Atrizco MD, Rubio-Poo C, Wertheimer AI.
Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Res Social Adm Pharm 2006 Mar; 2:(1):22-37
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17138499&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL12209
Bálint GP, Kean WF, Buchanan WW.
Sir William Osler (1849-1919): his opinion of modern therapeutics.
Scott Med J 2006 Mar; 51:(1):51-3
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16562428
HSL17539
Girona-Brumós L, Ribera-Montañá R, Carlos Juárez-Giménez J, Pilar Lalueza-Broto M.
[Positive and negative aspects of pharmaceutical services in Spain: about antidepressants and antipsychotics].
Gac Sanit 2006 Mar; 20:
http://www.elsevier.es/revistas/ctl_servlet?_f=7264&articuloid=13086038&revistaid=138
HSL10859
Pollard R.
Doctors fear run on quick-fix diet pill
Sydney Morning Herald 2006 Feb 28
http://www.smh.com.au/news/national/doctors-fear-run-on-quickfix-diet-pill/2006/02/27/1141020023615.html
HSL3839
In India, Selling Generics Used To Be So Easy
Business Week online 2006 Feb 27
http://yahoo.businessweek.com/magazine/content/06_09/b3973078.htm
HSL3843
Changing Rules Of Engagement Between Government,industry And NHS To Provide Best Treatment For Patients, UK
Medical News Today 2006 Feb 26
http://www.medicalnewstoday.com/medicalnews.php?newsid=38312
HSL3836
Coleman D.
Guidelines for Yale Physician Interactions with Pharmaceutical Industry
Yale University 2006 Feb 25
http://www.yale.edu/opa/newsr/06-01-25-02.all.html
HSL3842
Sahm P.
Level Of Osteoarthritis Pain May Determine Efficacy Of Glucosamine, Chondroitin Sulfate
Medical News Today 2006 Feb 25
http://www.medicalnewstoday.com/medicalnews.php?newsid=38267
HSL4788
Rothman KJ, Evans S.
More on JAMA's policy on industry sponsored studies.
BMJ 2006 Feb 25; 332:(7539):489
http://http://bmj.bmjjournals.com/cgi/content/full/332/7539/489-a
HSL4789
Brettingham M.
Doctor sues for unfair dismissal claiming Roche feared she would blow the whistle.
BMJ 2006 Feb 25; 332:(7539):441
http://bmj.bmjjournals.com/cgi/content/full/332/7539/441
HSL3830
Petition on editorial autonomy at the CMAJ
2006 Feb 24
http://www.chaps.ucalgary.ca/cmaj.htm
HSL4836
Mathews AW, Westphal SP.
Tricky FDA debate: should a risky drug be approved again?
Wall St J (East Ed) 2006 Feb 24; :B1,:
HSL5060
Nunnery J, Angulo FJ, Tollefson L.
Public health and policy.
Prev Vet Med 2006 Feb 24; 73:(2-3):191-5
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TBK-4HG6H76-1&_coverDate=02%2F24%2F2006&_alid=411423116&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5145&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4e2274b9e428c0efe7b1303efbcb58e9
HSL3837
Capell K.
Novartis: Medicine for the People
Business Week online 2006 Feb 22
http://yahoo.businessweek.com/globalbiz/content/feb2006/gb20060222_568670.htm
HSL3838
Herper M, Langreth R.
New England Journal Reaffirms Merck Concerns
Forbes.com 2006 Feb 22
http://www.forbes.com/technology/sciences/2006/02/22/merck-vioxx-0222markets05.html
HSL3848
Dispute raises concerns on drug-funded studies
Associated Press 2006 Feb 22
http://www.msnbc.msn.com/id/11506384/
HSL3849
Burton T.
Amid Alarm Bells, A Blood Substitute Keeps Pumping
The Wall Street Journal 2006 Feb 22
http://online.wsj.com/article/SB114057765651379801.html
HSL4790
Sauter B.
Growth hormone for 'antiaging'.
JAMA 2006 Feb 22; 295:(8):889
http://jama.ama-assn.org/cgi/content/full/295/8/889-a
HSL4837
Burton TM.
Amid alarm bells, a blood substitute keeps pumping; ten in trial have heart attacks, but data aren't published; FDA allows a new study; doctors' pleas are ignored.
Wall St J (East Ed) 2006 Feb 22; A1:
HSL4861
Sandstrom H.
[More than 1 out of 100 will have myocardial infarction and stroke because of enalapril--effect of drug package inserts?]
Lakartidningen 2006 Feb 22-28; 103:(8):564,
HSL3827
Canadian Medical Association Journal fires 2 editors
CBC News Online 2006 Feb 21
http://www.cbc.ca/story/science/national/2006/02/21/cmaj060221.html
HSL3833
Thomaselli R.
Glaxo drafts employees to polish industry image.
The Age (Melbourne) 2006 Feb 21
http://www.adage.com/news.cms?newsId=47970
HSL5610
Palmlund I.
Loyalties in clinical research on drugs: The case of hormone replacement therapy
Social Science & Medicine 2006 Feb 21;
HSL3829
Experts call for regulation of baby gender tests
ABC Action News 2006 Feb 20
http://www.abcactionnews.com/stories/2006/02/060220babyfolo.shtml
HSL3825
Diani H.
Embattled BPOM chief says agency doing its job to monitor drugs
The Jakarta Post 2006 Feb 18
http://www.thejakartapost.com/yesterdaydetail.asp?fileid=20060214.B02
HSL4602
Lenzer J.
US agency launches initiative on better prescribing for hypertension.
BMJ 2006 Feb 18; 332:(7538):379
http://bmj.bmjjournals.com/cgi/content/full/332/7538/379-a/DC1
HSL4603
Day M.
Industry association suspends drug company for entertaining doctors.
BMJ 2006 Feb 18; 332:(7538):381
http://bmj.bmjjournals.com/cgi/content/full/332/7538/381-a
HSL4791
Charatan F.
FDA committee votes for warning labels on stimulant drugs.
BMJ 2006 Feb 18; 332:(7538):380
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3051&uid=16484248&db=PubMed&url=http://bmj.com/cgi/pmidlookup?view=long&pmid=16484248
HSL3819
McConnaughy J.
Merck Cleared in 1st Federal Vioxx Case
Associated Press 2006 Feb 17
http://biz.yahoo.com/ap/060217/vioxx_federal_trial.html?.v=2
HSL3820
Zieminski N.
Lilly CEO says too much focus on drug side effects
Reuters 2006 Feb 17
http://today.reuters.com/business/newsarticle.aspx?type=reutersEdge&storyID=2006-02-17T142009Z_01_N16232854_RTRUKOC_0_US-ELILILLY-CEO.xml
HSL3831
Prescription Drugs: Nine States Looking Into Pharmaceutical Company Gifts to Physicians
kaisernetwork.org ( The Henry J. Kaiser Family Foundation) 2006 Feb 17
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=35488
HSL3835
Harris G.
Device Won Approval Though Staff Objected
New York Times 2006 Feb 17
http://topics.nytimes.com/top/reference/timestopics/people/h/gardiner_harris/index.html?inline=nyt-per
HSL4982
Guglielmo WJ.
Scheduling drug reps online.
Med Econ 2006 Feb 17; 83:(4):49-50,
HSL3821
Larsson J.
Eli Lilly's Strattera - 130 reports of suicidality in one month
24-7 Press Release Newswire 2006 Feb 16
http://www.24-7pressrelease.com/view_press_release.php?rID=11216
HSL3822
Don't get sick
The Jakarta Post 2006 Feb 16
http://www.thejakartapost.com/yesterdaydetail.asp?fileid=20060216.E02
HSL7824
Appleby J.
States want info about drugmakers' gifts to doctors
USA Today 2006 Feb 16
http://www.usatoday.com/money/industries/health/2006-02-16-doctor-gifts-usat_x.htm
HSL3824
Irving R.
Exanta withdrawn after liver damage to patient
Times Online 2006 Feb 15
http://business.timesonline.co.uk/article/0,,9068-2040896,00.html
HSL4987
Berenson A.
A cancer drug shows promise, at a price that many can't pay.
NY Times (Print) 2006 Feb 15; A1:
HSL5147
San Miguel MT, Vargas E.
Drug evaluation and approval process in the European Union.
Arthritis Rheum 2006 Feb 15; 55:(1):12-4
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3058&uid=16463405&db=PubMed&url=http://dx.doi.org/10.1002/art.21712
HSL3823
Diani H.
Pill-popping public 'victims of unregulated market'
The Jakarta Post 2006 Feb 14
http://www.thejakartapost.com/yesterdaydetail.asp?fileid=20060214.B01
HSL3826
Overmedication of children does more harm than good
The Jakarta Post 2006 Feb 14
http://www.thejakartapost.com/yesterdaydetail.asp?fileid=20060214.B03
HSL4793
Calon F.
Nonpatentable drugs and the cost of our ignorance.
CMAJ 2006 Feb 14; 174:(4):483-4
http://www.cmaj.ca/cgi/content/full/174/4/483
HSL4794
Sibbald B.
The vexations of Vioxx.
CMAJ 2006 Feb 14; 174:(4):444-5
http://www.cmaj.ca/cgi/content/full/174/4/444-a
HSL4925
Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates DW.
Adherence to black box warnings for prescription medications in outpatients.
Arch Intern Med 2006 Feb 13; 166:(3):338-44
http://archinte.ama-assn.org/cgi/content/full/166/3/338
HSL4999
Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM.
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Arch Intern Med 2006 Feb 13; 166:(3):332-7
http://archinte.ama-assn.org/cgi/content/full/166/3/332
HSL3817
A Surprising Warning on Stimulants
New York Times 2006 Feb 12
http://www.nytimes.com/2006/02/12/opinion/12sun2.html?_r=1&oref=slogin&pagewanted=print
HSL3834
Knightly P.
Bitter pill: The big business of Big Pharma
Khaleej Times online 2006 Feb 11
http://www.khaleejtimes.com/DisplayArticle.asp?xfile=data/opinion/2006/February/opinion_February33.xml§ion=opinion&col=
HSL4761
Dyer O.
Watchdog rules that Merck violated the UK industry code of practice.
BMJ 2006 Feb 11; 332:(7537):323
http://bmj.bmjjournals.com/cgi/content/full/332/7537/323-a
HSL4885
Atkinson M, Bevan R, Becker S, Breitz L, Brennan P, Crisp J, Etherton C, Ellis R, Feran K, Frazer E, Freiburger P, Garber K, Geekie M, Giedrys-Leeper E, Greenwall L, Grundy B, Heffernan M, Hetherington I, Hill G, Kidd A, Moxham D, Olesen N, Paolella T, Ro
Commercialism in marketing.
Br Dent J 2006 Feb 11; 200:(3):124-5
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3094&uid=16474320&db=PubMed&url=http://dx.doi.org/10.1038/sj.bdj.4813243
Page 94 of 144 pages ‹ First < 92 93 94 95 96 > Last ›
